Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CEA-C202 | Human | ClinMax™ Human PCSK9 ELISA Kit | |||
| PC9-H52H7 | Human | Human PCSK9 Protein, His Tag |  |
|
|
| EP-103 | Human | PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair | |||
| PC9-H5256 | Human | Human PCSK9 Protein, Fc Tag |  |
|
|
| PC9-H52E4 | Hamster | Hamster PCSK9 Protein, His Tag |  |
|
|
| PC9-C5223 | Cynomolgus | Cynomolgus PCSK9 Protein, His Tag |  |
|
|
| PC9-M82E1 | Mouse | Biotinylated Mouse PCSK9 Protein, Avitag™,His Tag |  |
|
|
| PCY-H5225 | Human | Human PCSK9 (D374Y) Protein, His Tag (MALS verified) |  |
|
|
| PC9-C52H2 | Rhesus macaque | Rhesus macaque PCSK9 Protein, His Tag |  |
|
|
| PC9-R52H4 | Rat | Rat PCSK9 Protein, His Tag |  |
|
|
| PCY-H82E7 | Human | Biotinylated Human PCSK9 (D374Y) Protein, Avitag™,His Tag |  |
|
|
| PC9-H82E7 | Human | Biotinylated Human PCSK9 Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| PC9-M5228 | Mouse | Mouse PCSK9 Protein, His Tag |  |
|
|
| PC9-H5223 | Human | Human PCSK9 Protein, His Tag (MALS verified) |  |
|
|
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | Mainland China | Atherosclerosis; Homozygous familial hypercholesterolemia | Amgen Inc | 2015-07-17 | Acute Coronary Syndrome; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Stroke; Homozygous familial hypercholesterolemia; Sepsis; Glioblastoma; Coronary Artery Disease; Hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Myocardial Infarction; Heart Failure; HIV Infections | Details |
| Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 波立达, Praluent | Mainland China | Dyslipidemias; Hypercholesterolemia; Atherosclerosis | Sanofi-Aventis Groupe | 2015-07-24 | Acute Coronary Syndrome; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Vascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hemorrhage; Stroke; Intracranial Arteriosclerosis; Homozygous familial hypercholesterolemia; Sepsis; Hypercholesterolemia; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Liver Diseases, Alcoholic; Plaque, Atherosclerotic; HIV Infections; Shock, Septic | Details |
| Inclisiran sodium | ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio | United States | Heterozygous familial hypercholesterolemia; Atherosclerosis | Novartis Pharma Ag | 2020-12-09 | Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Hypercholesterolemia; Kidney Diseases; Coronary Artery Disease; Acute Coronary Syndrome; Hypolipoproteinemias; Heterozygous familial hypercholesterolemia; Coronary Disease; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
| PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details | |
| SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
| NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
| Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Cardiovascular Diseases | Details | |
| Lodelcizumab | LGT-209; NVP-LGT-209 | Novartis Pharma Ag | Details | ||
| Recaticimab | SHR-1209 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| MEDI-4166 | MEDI-4166 | Medimmune Llc | Details | ||
| BMS-844421 | BMS-PCSK9; BMS 844421; BMSPCSK9Rx; ISIS-405879 | Ionis Pharmaceuticals Inc | Details | ||
| K-312 | K-312 | Kowa Co Ltd | Details | ||
| DC-371739 | DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias | Details |
| Ralpancizumab | RN 317; PF-5335810; PF-05335810 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| Ebronucimab | AK-102 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd, Yabao Us Pharmaceutical Co Ltd | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipidemia, Familial Combined | Details |
| MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
| Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined | Details |
| RBD-7022 | RBD-7022; RBD7022 | Phase 1 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypercholesterolemia; Dyslipidemias; Kidney Failure, Chronic; Hyperlipidemias | Details |
| AZD-0780 | AZD0780; AZD-0780 | Phase 1 Clinical | Astrazeneca Plc | Dyslipidemias | Details |
| Lerodalcibep | LIB-003 | Phase 3 Clinical | Lib Therapeutics Llc | Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
| MK-0616 | MK-0616 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Atherosclerosis; Hypercholesterolemia; Kidney Diseases; Hyperlipoproteinemia Type II | Details |
| NNC0385-0434 | NNC0385-0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Arteriosclerosis | Details |
| Ongericimab | JS-002 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Hypertriglyceridemia; Atherosclerosis; Hypercholesterolemia; Neoplasms; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
| ATH-04 | ATH-04 | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
This web search service is supported by Google Inc.
A-Z
